(MedPage Today) — An oral investigational agent, gildeuretinol (ALK-001), demonstrated a significant reduction in geographic atrophy (GA) lesion growth and improvements in low luminance visual function in the phase II SAGA trial, according to…
Source link : https://www.medpagetoday.com/meetingcoverage/arvovideopearls/115716
Author :
Publish date : 2025-05-22 15:58:00
Copyright for syndicated content belongs to the linked Source.
